Gyre Therapeutics

Gyre Therapeutics Inc is a commercial-stage pharmaceutical company developing and commercializing small-molecule anti-inflammatory and anti-fibrotic drugs targeting organ diseases, focusing specifically on organ fibrosis. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenue from the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other.

Gamestop, Lululemon, Uber, Ulta Beauty And Tesla: Why These 5 Stocks Are On Investors' Radars Today

News

Intraday Update

Markets

Movers

Trading Ideas

ACLX

ALGT

ANGO

CGNT

CIEN

COOP

CRWV

CYTK

GYRE

RDFN

SANA

Cognyte Software Posts Upbeat Results, Joins AngioDynamics, Allegiant Travel And Other Big Stocks Moving Higher On Wednesday

S&P 500 Earnings Growth

Equities

Eurozone

Commodities

ADTX

FINV

HROW

HUYA

SRPT

S&amp;P 500 Down 1%; Sarepta Therapeutics Shares Plunge

AIOT

APLT

BLCO

IAUX

LUNR

TERN

VSCO

Applied Therapeutics, PowerFleet, VF Corp, Victoria&#39;s Secret And Other Big Stocks Moving Higher On Wednesday

Gyre Therapeutics Inc

Events

Press Releases

Sidoti Events, LLC's Virtual August Micro-Cap Conference

Gyre Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference

Gyre Therapeutics to Present at 8th Annual H.C. Wainwright MASH Investor Conference

Health Care

Gyre Therapeutics Announces Last Patient Completed Pivotal Phase 3 Trial Evaluating F351 for CHB-Associated Liver Fibrosis

Earnings

Gyre Therapeutics Reports Third Quarter 2024 and Year-To-Date Financial Results and Provides Business Update

Management

Gyre Therapeutics Announces the Appointment of Ping Zhang to Board of Directors

Gyre Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Gyre Therapeutics Announces Publication of Protocol for Phase 3 Trial Evaluating F351 for CHB-Associated Liver Fibrosis in Journal of Clinical and Translational Hepatology

Gyre Therapeutics Announces NMPA Approval for Clinical Trial Evaluating Pirfenidone Capsules in Oncology-Related Pulmonary Complications

Gyre Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

BYRN

COOT

DTIL

GNPX

KELYA

KMDA

RNGR

SNCR

SONX

TRIB

TSX:MG

Ardelyx

Anavex Life Sciences Corp. - Common Stock

Anavex Life Sciences

Bicara Therapeutics

CareDx

Celldex Therapeutics, Inc. - Common Stock

Celldex Therapeutics

Dynavax Technologies Corporation - Common Stock

Dynavax Technologies

Dyne Therapeutics

89bio

Geron

GRAIL

Janux Therapeutics

MiMedx Group

Mineralys Therapeutics, Inc. - Common Stock

Mineralys Therapeutics

Nurix Therapeutics

Intellia Therapeutics, Inc. - Common Stock

Intellia Therapeutics

Novavax

Praxis Precision Medicines, Inc. - Common Stock

Praxis Precision Medicine

Rocket Pharmaceuticals, Inc. - Common Stock

Rocket Pharmaceuticals

Arcus Biosciences

Syndax Pharmaceuticals, Inc. - Common Stock

Syndax Pharmaceuticals

ARS Pharmaceuticals

Spyre Therapeutics

Vera Therapeutics, Inc. - Class A Common Stock

Vera Therapeutics

Viridian Therapeutics, Inc. - Common Stock

Viridian Therapeutics

Zymeworks

Comments

Gyre Therapeutics

Connect With Us

About Benzinga

Market Resources

Trading Tools & Education

Ring the Bell